Amgen Increases Prices (Again), Humana Flexes Muscle, and MIT Starts a $150M Engine

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

BIO Leaders Defend Immigrants, Sarepta’s Smackdown, Pfizer Bets $500M on NC
Roche/Genentech’s Clever NTRK Strategy, Regeneron’s Ebola Win & PCR Pioneer Passes
Novartis’ No-No, Bayer Buys BlueRock, and Job Switches Galore
BioNTech Snags $320m, Roche/Spark Delay, & Summer Job Switches